Related Experiment Videos
Ovarian cancer: optimal chemotherapy in relapsed disease
P F Conte1, C Cianci, L Tanganelli
1Department of Oncology, S. Chiara Hospital and University, Pisa, Italy.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Particle Beam Re-irradiation in Oligo Recurrent Gynecological Malignancies.
Clinical oncology (Royal College of Radiologists (Great Britain))·2026
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2023
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026